科创200

InnoCare Pharma's ICP-488 Completes First Patient Dosing in Phase II Trial for Cutaneous Lupus

Exx Robotics and Opto Signs Strategic Agreement to Jointly Promote Embodied AI Industrial Solutions

InnoCare's ICP-054 Completes First Patient Enrollment

CanSino Biologics' Adolescent and Adult Td5cp Vaccine NDA Gets Priority Review

CanSino's DTaP-Hib Vaccine Added to Priority Review

ZHIYANG INNOVATION to release FY2025 earnings report on May 18 During-Market BJT, forecast revenue CNY 1.17 B, EPS CNY 0.28

Nocile Jianhua's TYK2 Inhibitor Approved for Phase II Clinical Trials in Treating Sjogren's Syndrome

BYD Joins as a Shareholder of Hubei Huasheng Xianghe New Energy Material Co., Ltd.

Nocia Health's Innovative Drug ICP-B208 Approved for Clinical Trials

UBS Downgrades CanSino Biologics 2026 Target Price to HKD 52.4

PRIMARIUS released FY2026 Q1 earnings on April 29 After-Market (BJT), actual revenue CNY 100.65 M, actual EPS CNY -0.028

Olymvax Biopharmaceuticals released FY2026 Q1 earnings on April 29 After-Market (BJT), actual revenue CNY 157.8 M, actual EPS CNY 0.0671

JSCQ released FY2026 Q1 earnings on April 29 After-Market (BJT), actual revenue CNY 247.7 M, actual EPS CNY 0

TRANSWARP TECHNOLOGY released FY2026 Q1 earnings on April 29 After-Market (BJT), actual revenue CNY 81.25 M, actual EPS CNY -0.46

Hangzhou Kelin released FY2026 Q1 earnings on April 29 After-Market (BJT), actual revenue CNY 44.88 M, actual EPS CNY -0.02

Genrix Bio released FY2026 Q1 earnings on April 29 After-Market (BJT), actual revenue CNY 67.25 M, actual EPS CNY -0.41

GCH released FY2026 Q1 earnings on April 29 After-Market (BJT), actual revenue CNY 249.18 M, actual EPS CNY 0.49

GUIZHOU ZHENHUA FENGGUANG SEMICONDUCTOR released FY2026 Q1 earnings on April 29 After-Market BJT, actual revenue CNY 137.27 M, actual EPS CNY -0.0671

YUNLU MATERIALS released FY2026 Q1 earnings on April 29 After-Market (BJT), actual revenue CNY 468.26 M, actual EPS CNY 0.52

UNION SEMICONDUCTOR (HEFEI) released FY2026 Q1 earnings on April 29 After-Market (BJT), actual revenue CNY 410.92 M, actual EPS CNY -0.01

588240

TSMU

159516

SOXX

TSMX

588170

TSMG

This Thursday, TSMC executives announced at the earnings conference that capital expenditures are expected to approach USD 52 billion to USD 56 billion in 2026. Global semiconductor equipment sales are projected to grow by 8% year-on-year in the fourth quarter of 2025, with the Chinese market growing by 11%. The Penghua SSE Science and Technology Innovation Board 200 ETF rose by 0.83%, with the latest price at CNY 1.69, closely tracking the SSE STAR 200 Index, which reflects the overall performance of listed companies of different market capitalizations in the STAR Market

腾讯新闻 - 财经

Penghua SSE Science and Technology Innovation Board 200 ETF

GraniteShares 2x Long TSM Daily ETF

Guotai CSI Semiconductor Material Equipment Theme ETF

SPDR S&P Semicon

iShares Semiconductor ETF

VanEck Semiconductor ETF

Direxion Daily TSM Bull 2X Shares

ChinaAMC SSE STAR Semiconductor Material & Equipment Thematic ETF

Leverage Shares 2X Long TSM Daily ETF

Taiwan Semiconductor

CCSC

Everbright

RIGOL

SM Micro

SIGLENT

STAR 50

STAR 100

OPTOWIDE

Focuslight

TACLINK

SEICHITECH

UCloud

Guangdong Jiayuan Technology

Fusion

TZTEK

CC SECURITIES

Penghua SSE Science and Technology Innovation Board 200 ETF rose nearly 1%, TSMC's capital expenditure for 2026 is approaching peak levels

NVDL

159998

Penghua SSE Science and Technology Innovation Board 200 ETF rose by 1.76%, tracking the Shanghai Stock Exchange Science and Technology Innovation Board 200 Index. The computing power concept has exploded across the board, with the industry chain maintaining high prosperity and demand exceeding supply. The rental prices of NVIDIA GPUs have increased, driving a surge in Token usage. It is expected that by 2026, the shipment volume of domestic computing power chips will double, driving growth in related industries. The Shanghai Stock Exchange Science and Technology Innovation Board 200 Index rose by 1.79%, with constituent stocks performing strongly

GraniteShares 2x Long NVDA Daily ETF

Tianhong CSI Computer Theme ETF

Direxion Semicon Bull 3X

Guotai CSI Computer Theme ETF

T-Rex 2X Long NVIDIA Daily Target ETF

Guotai CES Semiconductor Chip Industry ETF

GTJA Allianz SSE STAR Chip Design Thematic ETF

Direxion Daily NVDA Bull 2X Shares

GTJA Allianz CSI All Share Semiconductors & Semiconductor Equipment ETF

NVIDIA

CITIC Securities Co., Ltd.

CITIC SEC

Dingtong

Freewon

IECHO

GDTC

Breo

NVIDIA Corporation

Penghua SSE Science and Technology Innovation Board 200 ETF rose over 1.7%, and the computing power concept surged across the board today

159227

563530

Today, the Penghua SSE Science and Technology Innovation Board 200 ETF rose by 0.56%, with sectors such as power equipment, military industry, and chemicals leading the gains. The Long March 10 B rocket has arrived in Hainan and is confirmed to make its maiden flight at the end of April. The price increase of storage chips exceeded expectations, with both DRAM and NAND Flash contract prices significantly raised. The SSE Science and Technology Innovation Board 200 may experience short-term fluctuations and corrections, but the medium to long-term outlook is optimistic for upward movement. The SSE Science and Technology Innovation Board 200 Index rose by 0.51%, with constituent stocks generally increasing

ChinaAMC CNI Aerospace ETF

E Fund CSI Satellite Industry ETF

Penghua SSE Science and Technology Innovation Board 200 ETF closed in the green today, with the power equipment, military industry, and chemical sectors leading the market

688046

688690

The Science and Technology Innovation Board 200 ETF performed excellently in the bull market, rising nearly 1%. This index consists of 200 technology stocks with smaller market capitalizations and good liquidity, primarily concentrated in emerging industries such as electronics, pharmaceuticals, and biotechnology. The Science and Technology Innovation Board 200 has shown better recovery performance in the bull market compared to other indices, indicating higher earnings elasticity. Its constituent stocks, such as NANOMICRO and GEMPHARMATECH, have both seen significant increases, reflecting the market's strong preference for technology stocks

GEMPHARMATECH

NANOMICRO

The characteristics of small and micro-cap technology stocks combined with the bull market's oversold recovery pioneer, the Penghua SSE Science and Technology Innovation Board 200 ETF rose nearly 1%

000690

588080

科创综指

000698

000688

588210

588270

On April 9th, the series of STAR Market indices collectively adjusted, with the STAR Growth Index falling by 0.2%, the STAR 100 Index down by 0.5%, the STAR 50 Index decreasing by 0.7%, the STAR Composite Index dropping by 0.8%, and the STAR 200 Index experiencing a decline of 0.9%. Despite short-term fluctuations, the earnings expectations for the STAR 50 constituent stocks have improved, with projected operating revenue expected to grow by 21.53% year-on-year in 2026, and net profit attributable to the parent company significantly increasing to 98.68%. The relevant ETFs under E Fund have performed excellently, with the industry distribution and key indicators of the STAR 50 ETF, STAR 100 ETF, and STAR 200 ETF demonstrating their investment value

STAR Growth Index

E Fund China Science and Technology Innovation Board 50 Component ETF

E Fund SSE Science and Technology Innovation Board 100 ETF

E Fund SSE Science and Technology Innovation Board 200 ETF

The STAR Market index collectively adjusted, and profit expectations have warmed up

Penghua SSE Science and Technology Innovation Board 200 ETF rose by 3.41%, with risk assets making a strong comeback. The situation between the U.S. and Iran has improved, leading to a price surge in the semiconductor industry chain, with multiple domestic and foreign companies issuing price adjustment notices. The usage of AI large models increased by over 31% month-on-month, and Guosen Securities predicts that the global semiconductor industry will enter the trillion-dollar era by the end of 2026. The Shanghai Stock Exchange Science and Technology Innovation Board 200 Index rose by 3.58%, with strong performance from constituent stocks, and the top ten weighted stocks accounted for a total of 16.73%

Penghua SSE Science and Technology Innovation Board 200 ETF rose over 3.4%, risk assets make a strong comeback

516930

588130

The Penghua SSE Science and Technology Innovation Board 200 ETF closed in the green today, with the chemical and electronics sectors leading the gains. The pharmaceutical and biotechnology sectors continue to show strength, and innovative drugs are entering a data catalyst period. The situation in the Middle East has raised concerns about resources, leading to panic buying in the domestic helium market. It is expected that SABIC will be affected by natural gas issues, resulting in a production halt impacting 25-30% of capacity, which will initiate price increases for high-end resins. Looking ahead, the SSE Science and Technology Innovation Board 200 is expected to experience short-term fluctuations and corrections, with the mid-term index center likely to shift upward. As of April 7, 2026, the SSE STAR 200 Index has risen by 0.35%, and the Penghua SSE Science and Technology Innovation Board 200 ETF has increased by 0.13%

Minsheng Royal CSI Biotechnology Theme ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Yinhua CSI Innovative Drugs Industry ETF

Guotai CSI Bio-medicine ETF

ICBCCS SSE STAR Biology and Medicine ETF

E Fund CSI Biotechnology Theme ETF

E Fund CSI 300 Health Care ETF

China Merchants CSI Biotechnology Theme ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

ChinaAMC CSI Biotechnology Theme ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Penghua SSE STAR Biology and Medicine ETF

Tianhong CNI BIOMEDICINE ETF

Ping An CSI Medicine and Medical Device Innovation ETF

Penghua SSE Science and Technology Innovation Board 200 ETF closed in the green today, with weighty sectors such as chemicals and electronics leading the gains

589700

588880

This week, the market faced pressure, with most leading hard technology stocks experiencing a pullback, but small-cap technology stocks performed relatively strongly. The STAR 200 ETF (588270) is worth paying attention to. Major STAR indices all saw declines, with the STAR 200 index down 0.6%, the STAR Growth index down 0.8%, the STAR 100 index down 1.9%, the STAR Composite index down 1.9%, and the STAR 50 index down 3.4%. Investment should be cautious, and funds carry risks

China Southern SSE STAR Growth ETF

Huatai-PB SSE Science and Technology Innovation Board 100 ETF

Small-cap technology stocks have been relatively active this week, focusing on the investment value of E Fund SSE Science and Technology Innovation Board 200 ETF (588270)

159316

159615

The Penghua SSE Science and Technology Innovation Board 200 ETF is actively traded, with the pharmaceutical sector performing outstandingly against the market trend. In 2025, China's innovative drug BD overseas licensing reached a historic high, with a total transaction amount exceeding 60 billion USD. Eli Lilly's GLP-1 oral medication has been approved by the FDA. The market has shown weak performance due to external negative factors and cautious observation ahead of the holiday, resulting in light trading. Looking ahead, if external disturbances decrease, the SSE Science and Technology Innovation Board 200 ETF is expected to rise. The latest quote for the Penghua SSE Science and Technology Innovation Board 200 ETF is 1.51 yuan, featuring a "hard technology" logic and a "20% price fluctuation limit" elasticity, with a balanced industry distribution, and the pharmaceutical sector accounting for nearly 15%

E Fund Hang Seng SCHK Innovative Drug ETF

China Southern Hang Seng Biotech ETF(QDII)

Invesco Nasdaq Biotechnology ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Direxion S&P Biotech Bull 3X

VG Health

Eli Lilly

iShares Biotechnology ETF

Ark Genomic Revolution ETF

Proshares Ultra Nasdaq Biotech

ALPS Medical Breakthrough

VanEck Biotech ETF

Direxion S&P Biotech Bear 3X

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

First Trust NYSE Arca Biotech Index Fd

Defiance Daily Target 2X Long LLY ETF

iShares US Pharma

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Invesco Biotechnology & Genome ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Health Care Select Sector SPDR

SPDR S&P Biotech

The Science and Technology Innovation 200 ETF by Penghua is actively traded, with the pharmaceutical sector performing well against the market trend

The innovative drug concept performed strongly in the early trading session, influenced by the upcoming American Association for Cancer Research annual meeting. Over 100 Chinese pharmaceutical companies will participate, bringing nearly 400 research results. Guosheng Securities pointed out that the total amount of innovative drug BD licensing will exceed USD 60 billion in the first quarter of 2026, with global cooperation value accelerating to be realized. The Penghua SSE Science and Technology Innovation Board 200 ETF rose by 2.63%, with the latest price reported at 1.52 yuan, closely tracking the SSE Science and Technology Innovation Board 200 Index, which has the top ten weighted stocks accounting for a total of 16.73%

Penghua SSE Science and Technology Innovation Board 200 ETF rose over 2.6%, with the innovative drug concept strongly surging

科创200(000699.SH)

Penghua SSE Science and Technology Innovation Board 200 ETF rose nearly 1%, TSMC's capital expenditure for 2026 is approaching peak levels

Penghua SSE Science and Technology Innovation Board 200 ETF rose over 1.7%, and the computing power concept surged across the board today

Penghua SSE Science and Technology Innovation Board 200 ETF closed in the green today, with the power equipment, military industry, and chemical sectors leading the market

The characteristics of small and micro-cap technology stocks combined with the bull market's oversold recovery pioneer, the Penghua SSE Science and Technology Innovation Board 200 ETF rose nearly 1%

The STAR Market index collectively adjusted, and profit expectations have warmed up